Analysis of Hodgkin’s Lymphoma (Hodgkin’s B-Cell Lymphoma) Clinical Trials by Trial Phase, Trial Status, Number of Trials, Endpoints, Status, Sponsor Type, and Top Countries, 2022 Update – ResearchAndMarkets .com | Nation/World

DUBLIN–(BUSINESS WIRE)–August 23, 2022–

The “Analysis of clinical trials in Hodgkin’s lymphoma (Hodgkin’s B-cell lymphoma) by trial phase, trial status, number of trials, endpoints, status, sponsor type and top countries, 2022 update” report has been added to ResearchAndMarkets.comoffer.

The publisher’s clinical trial report, “Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) Clinical Trial Analysis by Trial Phase, Trial Status, Trial Counts, End Points, Status, Sponsor Type, and Top Countries, 2022 Update” gives an overview of Hodgkin’s Lymphoma (Hodgkin’s B-Cell Lymphoma) Clinical Trial Scenario.

This report provides key clinical trial data for Hodgkin lymphoma (Hodgkin B-cell lymphoma). The report includes an overview of the number of trials and their average enrollment in major countries conducted across the world. The report offers disease-specific clinical trial coverage by region, country (G7 and E7), phase, trial status, endpoint status and sponsor type. The report also provides leading drugs for ongoing trials (based on the number of ongoing trials). The publisher’s clinical trial reports are generated using the publisher’s proprietary database – Pharma – Clinical Trials Database. Clinical trials are collated from over 80 different clinical trial registries, conferences, reviews, news, and more. worldwide. The clinical trials database is periodically updated through a dynamic process.

The report enhances decision-making capabilities and helps in creating effective counter-strategies to gain competitive advantage.

Note: Certain sections of the report may be deleted or modified depending on the availability and relevance of data for the indicated disease.

Scope

• The report provides an overview of the global clinical trials landscape
• The report provides high-level clinical trial data by region, country (G7 and E7), trial status, trial phase, sponsor type and endpoint status
• The report reviews the main companies involved and lists all trials (trial title, phase and status) relating to the company
• The report provides all incomplete trials (completed, suspended and withdrawn) with the reason for the incompleteness
• Report shows enrollment trends over the past five years
• The report provides the latest news from the last three months

Note: Certain sections of the report may be deleted or modified depending on the availability and relevance of data for the indicated disease.

Reasons to buy

• Helps formulate key business strategies for investing
• Helps identify important locations for conducting clinical trials, saving time and money
• Provides high-level analysis of the global clinical trials market that helps identify key business opportunities
• Helps understand the number of trials and enrollment trends by country in the global therapeutics market
• Helps interpret clinical trial success rates by providing a comparative scenario of completed and incomplete trials (completed, suspended or withdrawn)
• Facilitates the evaluation of clinical trials of the indication at global, regional and national level

Main topics covered:

1. Report Guide
2. Cover of the GlobalData report on clinical trials
3. Clinical trials by region
4. Clinical trials and average recruitment by country
5. Clinical trials by G7 country: Proportion of Hodgkin’s lymphomas (Hodgkin’s B-cell lymphomas) compared to clinical trials in oncology
6. Clinical trials by phase in G7 countries
7. Clinical trials in G7 countries by trial status
8. Clinical trials by E7 country: Proportion of Hodgkin’s lymphoma (Hodgkin’s B-cell lymphoma) compared to clinical trials in oncology
9. Clinical trials by phase in E7 countries
10. Clinical trials in E7 countries by trial status
11. Clinical trials by phase
12. Ongoing trials by phase
13. Clinical trials by trial status
14. Clinical Trials by Endpoint
15. Subjects recruited over a period of time
16. Clinical trials by type of sponsor
17. Leading Sponsors
18. Top Companies Participating in Clinical Trials for Hodgkin Lymphoma (Hodgkin B-Cell Lymphoma) Therapeutics
19. Important drugs
20. Clinical Trials Profile Snapshots
21. Annex
22. Abbreviations
23. Definitions
24. Research Methodology
25. Secondary research
26. About the editor
27. Contact the editor
28. Disclaimer
29. Source

Companies cited

• Bristol-Myers Squibb Co.
• Takeda Pharmaceutical Co Ltd
• Seagen Inc.
• Merck & Co Inc.
• Novartis AG
• Amgen Inc.
• F. Hoffmann-La Roche SA
• Sanofi
• Pfizer Inc.
• Astra Zeneca Plc

For more information on this report, visit https://www.researchandmarkets.com/r/jeptxi

Show source version on businesswire.com:https://www.businesswire.com/news/home/20220823005633/en/

CONTACT: ResearchAndMarkets.com

Laura Wood, Senior Press Officer

[email protected]

For EST business hours, call 1-917-300-0470

For US/CAN call toll free 1-800-526-8630

For GMT office hours call +353-1-416-8900

KEYWORD:

INDUSTRY KEYWORD: CLINICAL TRIALS IN ONCOLOGY HEALTH PHARMACEUTICALS

SOURCE: Research and Markets

Copyright BusinessWire 2022.

PUBLISHED: 08/23/2022 10:21 a.m. / DISK: 08/23/2022 10:21 a.m.

http://www.businesswire.com/news/home/20220823005633/en

Copyright BusinessWire 2022.